Memantine's the first in a novel class of Alzheimer's disease medications acting on the glutamatergic system by blocking NMDA glutamate receptors. Memantine's marketed under the brands Axura and Akatinol by Merz, Namenda by Forest, Ebixa and Abixa by Lundbeck and Memox by Unipharm. Clinical use Although memantine's approved for treatment of moderate to severe Alzheimer's disease, its usage has been recommended against by the UK's National Institute for Clinical Excellence, on the grounds that i… (More on Memantine)